Argenx is taking significant strides in the bio-tech industry. The Belgium-based clinical-stage biopharmaceutical company is actively gearing up for the launch of
Vyvgart, which designates a potential indication. Also, the company readies a
blockbuster opportunity with a drug for autoimmune diseases. Despite a decline by 23% in Q4, the company bounced back, showing strength with its stock moving about 11% upwards. However, Argenx's Phase III trial for pemphigus failed to meet the endpoint leading to a plummet in stock prices by a third. This was followed by Vyvgart's failure to achieve both primary and secondary endpoints in a Phase III trial. On a brighter note,
Vyvgart received approval in Japan for adults with primary immune thrombocytopenia and gMG treatment. The company has raised $1.1B through stock placement after a CIDP trial win, and it continues making progress in its pipeline. Notwithstanding two clinical trial failures, Argenx receives positive evaluation from 12 analysts who share rosy views about the company’s prospects. Dutifully, Argenx continues to transform patient expectations, securing its footing as a key player in the Autoimmunity at the American Academy of Neurology.
argenx News Analytics from Mon, 17 Jul 2023 07:00:00 GMT to Sat, 25 May 2024 17:56:37 GMT -
Rating 3
- Innovation -3
- Information 7
- Rumor -2
